Welcome to our dedicated page for CURIS SEC filings (Ticker: CRIS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CURIS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CURIS's regulatory disclosures and financial reporting.
Curis, Inc. is a biotechnology company developing emavusertib for hematologic cancers, with ongoing combination trials in relapsed/refractory PCNSL and CLL and substantially complete AML studies. Emavusertib holds multiple Orphan Drug Designations in the U.S. and EU.
For the six months ended June 30, 2026, Curis reported a net loss of $32.8 million and no revenue, versus $5.1 million of royalty revenue a year earlier, reflecting the 2025 sale of Erivedge royalties. R&D expense fell 18% to $13.2 million, while G&A rose 10% to $8.3 million, partly from the January 2026 PIPE financing. A $11.5 million non‑cash loss from warrant remeasurement drove other expense.
Cash and cash equivalents were $5.1 million and total assets $19.0 million at June 30, 2026. After an August 2026 equity offering expected to add about $4.8 million, management believes liquidity funds operations only into the fourth quarter of 2026 and discloses substantial doubt about continuing as a going concern without additional capital.
Curis, Inc. is conducting a primary offering of 335,001 shares of common stock, 3,398,333 pre-funded warrants and 3,733,334 August 2026 common warrants, at a combined public offering price of $1.50 per share and warrant or $1.49 per pre-funded warrant and warrant, for total gross proceeds of $5.6 million. Net proceeds are estimated at $4.8 million after a 6.5% placement fee and expenses, and are intended to fund research and development for emavusertib, working capital and general corporate purposes.
The warrants are immediately exercisable, with pre-funded warrants priced at a $0.01 exercise price per share and August 2026 Warrants at $1.75 per share, expiring five years after issuance, and subject to 4.99%–9.99% beneficial ownership caps. As of March 31, 2026 Curis held $15.0 million in cash and equivalents, had an accumulated deficit of $1.3 billion, and reported a quarterly net loss of $24.2 million. The company states that existing cash plus this offering are not expected to fund operations beyond 12 months and explicitly discloses substantial doubt about its ability to continue as a going concern.
Curis, Inc. is registering up to 3,731,344 shares of common stock, up to 3,731,344 pre-funded warrants, up to 3,731,344 August 2026 common warrants, and up to 7,462,688 shares issuable upon warrant exercise in a best-efforts offering. Securities are priced off an assumed combined offering price of $4.02 per common share and warrant, implying estimated net proceeds of about $13.6 million if the maximum number of common shares is sold. Curis intends to use proceeds primarily for research and development of its lead candidate emavusertib (CA-4948) and for working capital.
The company is a biotechnology developer of an oral IRAK4/FLT3 inhibitor in Phase 1/2 PCNSL and Phase 2 CLL combination trials, with Orphan Drug Designations in several indications and regulatory feedback supporting potential accelerated pathways. As of March 31, 2026, Curis had $15.0 million in cash and cash equivalents, a net loss of $24.2 million for the quarter, and an accumulated deficit of $1.3 billion. Curis states its current liquidity raises substantial doubt about its ability to continue as a going concern and that this offering alone will not resolve that doubt beyond 12 months. A 1-for-20 reverse stock split was effected on July 2, 2026.
Curis, Inc. reports that on July 24, 2026 it received written notice from Nasdaq that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the bid price requirement, and is in full compliance with conditions set by a Nasdaq Hearings Panel.
Under Listing Rule 5815(d)(4)(A), Curis will be subject to a one-year Discretionary Panel Monitor starting July 24, 2026. If Curis fails to meet any continued listing requirement during this period, Nasdaq Staff will issue a Delist Determination Letter and the company must promptly request a new hearing before a Hearings Panel. During the monitor period Curis cannot submit a compliance plan and Staff cannot grant additional time to regain compliance. The company notes there can be no assurance that any appeal would succeed or that its stock will remain listed on Nasdaq, and it includes forward-looking statement cautions referencing risk factors in its Form 10-K for the year ended December 31, 2025.
Curis Inc. director Marc Rubin received a grant of stock options. He was awarded non-qualified options covering 6,800 shares of Curis common stock at an exercise price of $5.29 per share. The options vest 100% on July 7, 2027 and expire on July 6, 2036.
CURIS INC director Kenneth I. Kaitin reported receiving a grant of non-qualified stock options linked to the company’s common stock. The award covers 6,800 options with an exercise price of $5.29 per share, giving the right to acquire 6,800 shares of common stock.
The options vest as to 100% of the underlying shares on July 7, 2027 and carry an expiration date of July 6, 2036. Following this grant, the filing shows 6,800 derivative securities held directly, reflecting a routine compensation-related equity award rather than an open-market stock purchase or sale.
CURIS INC director John Hohneker received a grant of 6,800 non-qualified stock options with an exercise price of $5.29 per share. These options relate to 6,800 shares of common stock and were awarded as a grant or other acquisition, not an open-market purchase or sale.
The options vest as to 100% of the underlying shares on July 7, 2027, and are scheduled to expire on July 6, 2036. Following this award, Hohneker holds 6,800 derivative securities directly in the form of these options.
CURIS INC director Martyn D. Greenacre received a grant of options on 6,800 shares of common stock. These non-qualified stock options have an exercise price of $5.29 per share and expire on July 6, 2036. The options vest 100% on July 7, 2027, aligning compensation with longer-term performance.
CURIS INC director Anne Elizabeth Borgman received a grant of non-qualified stock options, acquiring rights to purchase 6,800 shares of common stock at an exercise price of $5.29 per share. These options vest 100% on July 7, 2027 and expire on July 6, 2036. Following this grant, her reported derivative holdings from this award total 6,800 options, reflecting compensation-related equity rather than an open-market purchase.